CHICAGO (EMGN) - The use of endocrine therapy plus zoledronic acid (Zometa) reduced the risk of relapse by 36% among premenopausal women with early stage, endocrine-responsive breast cancer in a randomized trial of more than 1,800 women. The Austrian Breast and Colorectal Cancer Study Group-12 trial examined whether aromatase inhibitors could improve clinical outcomes for breast cancer patients compared with tamoxifen and if bisphosphonates added to endocrine therapy could improve outcomes. Dr. Michael...